Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Sandip Patel, MD, describes the prominent safety challenges with administration of immunotherapies

Dr. Patel, Assistant Professor of Medicine, Deputy Director, San Diego Center for Precision Immunotherapy, Co-Leader, Experimental Therapeutics (Phase 1), UC San Diego Moores Cancer Center, elaborates on the most prominent safety challenges he is seeing with the administration of immunotherapies in advanced cancer patients

Tags: ASCO Palliative and Supportive Care Conference CoverageImmuno-oncology (includes cancer vaccines)Patient Care (includes Supportive Care, Palliative Care, Survivorship, QOL, Advocacy, Adverse Events, Pain Management)

Published: 30 October 2017

Recent Videos: ASCO Palliative and Supportive Care Conference Coverage

There have been no new videos in this category within the last 12 months.

Related Videos

video-image

Scott Tagawa, MD, on promising PSMA products in development for prostate cancer treatment

video-image

Scott Tagawa, MD, explains intravesical therapies being developed given there is a BCG shortage

video-image

Scott Tagawa, MD, shares results of phase 1 dose escalation study of 225Ac-J591 in metastatic prostate cancer patients

video-image

Bradley McGregor, MD, discusses Checkmate-214 investigating nivolumab + ipilimumab in 1st line renal cell carcinoma patients

video-image

David Quinn, MD, explains the impact of data being presented at ASCO GU20 regarding neoadjuvant bladder cancer

video-image

David Quinn, MD, on best utilization of stereotactic radiation in the management of advanced renal cell carcinoma patients

video-image

David Quinn, MD, discusses Checkmate-214 investigating nivolumab + ipilimumab in advanced renal cell carcinoma patients

video-image

David Quinn, MD, describes if biomarkers help guide treatment in advanced renal cell carcinoma

video-image

Tian Zhang, MD, on follow up investigation of Checkmate 025 in renal cell carcinoma patients

video-image

Bradley McGregor, MD, on metastatic renal cell cancer patients whose cancer returns and were previously treated with I-O

video-image

Michael Atkins, MD, shares exciting potential of current late-stage clinical studies in renal cell cancer patients

video-image

Michael Atkins, MD, on metastatic renal cancer patients whose cancer returns and were previously treated with I-O

video-image

Michael Atkins, MD, on appropriate patient types to receive a TKI in the treatment of 1st line RCC patients

video-image

Michael Atkins, MD, discusses the 4 year follow up of Checkmate-214 investigating nivolumab + ipilimumab in 1st line renal cell carcinoma patients

video-image

Tanya Dorff, MD, on the future of cellular immunotherapy versus checkpoint inhibition in mPC

video-image

Tanya Dorff, MD, shares thoughts of the optimal sequence of atezolizumab and sip-T in mCRPC

video-image

Oliver Sartor, MD, on the exciting recent outcomes investigating Lu-177–PSMA in patients with advanced prostate cancer

video-image

Arlene Siefker-Radtke, MD, shares the role of selecting mutations vs amplification for urothelial cancer treatment

video-image

Arlene Siefker-Radtke, MD, regarding the development of erdafitinib in bladder cancer

video-image

Robert Figlin, MD, shares exciting potential of current late-stage clinical studies in RCC patients

video-image

Robert Figlin, MD, on appropriate patient types to receive a TKI in the treatment of 1st line renal cell carcinoma patients

video-image

Lucia Nappi, MD, explains micro RNA usage to aid in the diagnosis and treatment of testicular cancer

video-image

Yung Lyou, MD, summarizes the EV103 study investigating enfortumab + pembrolizumab

video-image

Anis Hamid, describes how RNA profiling guides treatment decisions about chemotherapy for metastatic prostate cancer

video-image

Anis Hamid, MD, describes real world impact of immunotherapy when added to oral therapies for advanced prostate cancer

video-image

Daniel P. Petrylak, MD, explains the effect of second antigen spread in metastatic castration resistant prostate cancer patients

video-image

Daniel P. Petrylak, MD, shares potential efficacy when adding immunotherapy such as sip-T in metastatic castration resistant prostate cancer

video-image

Daniel P. Petrylak, MD, expresses the efficacy of infigratinib in FGFR3-altered metastatic urothelial cancer patients

video-image

Landon Brown, MD, shares real world evidence regarding immunotherapy, RCC, and brain metastasis

video-image

Bradley McGregor, MD, shares presented data investigating atezolizumab and cabozantinib in metastatic castration resistant prostate cancer

video-image

Oliver Sartor, MD, elaborates on presented data investigating atezolizumab and cabozantinib in metastatic castration resistant prostate cancer

video-image

Oliver Sartor, MD, regarding recent outcomes investigating 225Ac-PSMA-617 in patients with advanced prostate cancer

video-image

Landon Brown, MD, defines CTC chromosomal instability and neuroendocrine phenotype

video-image

Rana McKay, MD, elaborates on presented data investigating atezolizumab and cabozantinib in metastatic castration resistant prostate cancer

video-image

Rana McKay, MD, shares exciting potential of current late-stage clinical studies in RCC patients

video-image

Rana McKay, MD, discusses mRCC patients whose cancer returns and were previously treated with I-O

video-image

Rana McKay, MD, deliberates on patient types appropriate to receive a TKI in the treatment of RCC

video-image

Andrew Armstrong, MD, provides insight as to genetic testing to be conducted in a patient with metastatic prostate cancer

video-image

Andrew Armstrong, MD, shares updates on the ARCHES study investigating enzalutamide in metastatic prostate cancer patients

video-image

Andrew Armstrong, MD, on determining treatment of prostate cancer with DNA repair markers

video-image

Tom Beer, MD, explains whether PFS2 is a legitimate endpoint in prostate cancer clinical trials

video-image

Tom Beer, MD, shares impressions of the TITAN study invesigating 1st line therapy in mCRPC patients

video-image

Jeanny Aragon-Ching, MD, summarize the EV103 study investigating enfortumab + pembrolizumab

video-image

Jeanny Aragon-Ching, MD, explains efficacy and toxicities differences as they are used in NM-CRPC

video-image

Jeanny Aragon-Ching, MD, discusses STOMP trial data regarding surveillance vs directed therapy

video-image

Daniel P. Petrylak, MD, on the integration of liquid biopsy being targeted into the treatment of prostate cancer

video-image

Daniel P. Petrylak, MD, on the current role of circulating tumor cell components via liquid biopsy prostate cancer treatment

video-image

Oliver Sartor, MD, on future use of liquid biopsy into the treatment of prostate cancer

video-image

Tanya Dorff, MD, shares impressions of the CARD study investigating the role of cabazitaxel in mCRPC

video-image

Oliver Sartor, MD, shares impressions of the CARD study investigating the role of cabazitaxel in mCRPC

video-image

Anis Hamid, MD, on impressions of the CARD study investigating the role of cabazitaxel in mCRPC

video-image

Rana McKay, MD, shares impressions of the CARD study investigating the role of cabazitaxel in mCRPC

video-image

Andrew Armstrong, MD, shares impressions of the CARD study investigating cabazitaxel in metastatic castration-resistant prostate cancer patients

video-image

Tom Beer, MD, shares impressions of the CARD study investigating cabazitaxel in mCRPC patients

video-image

Nizar Tannir, MD, shares strategy of IO and TKIs when managing treatment of advanced RCC patients.

video-image

Jeanny Aragon-Ching, on the impact of the genomic classifier testing when choosing patients with mPC

video-image

David Quinn, MD, explains the use of FGFR in directing treatment algorithms in UC patients

video-image

Andrew Armstrong, MD, explains whether ARV-7 is predictive of response to taxanes in metastatic prostate cancer patients

video-image

Tian Zhang, MD, on the follow up study investigating nivolumab + ipilimumab in 1st line RCC patients

video-image

Nizar Tannir, MD, describes the 4 year follow up study of nivolumab + ipilimumab in RCC patients

video-image

David Quinn, MD, on impressions of phase I/II study of oral HIF-2 α inhibitor MK-6482 in patients with advanced clear renal cell carcinoma

video-image

Arlene Siefker-Radtke, MD, on how new data will impact treatment of neoadjuvant bladder cancer

video-image

Tanya Dorff, MD, elaborates on data investigating atezolizumab and cabozantinib in metastatic castration resistant prostate cancer

video-image

Michael Atkins, MD, on follow up investigation of Checkmate 025 in renal cell carcinoma patients

video-image

Bradley McGregor, MD, describes whether biomarkers help guide treatment in advanced renal cell carcinoma

video-image

Bradley McGregor, MD, on impressions of phase I/II study of oral HIF-2 α inhibitor MK-6482 in patients with advanced clear renal cell carcinoma

video-image

Tian Zhang, MD, elaborates on the PEDIGREE clinical study in advanced renal cell cancer patients

video-image

Oliver Sartor, MD, shares data of cellular immunotherapy within the African American population

video-image

Robert Figlin, MD, on treatment of returning metastatic renal cancer when previously treated with I-O

video-image

Lucia Nappi, MD, describes the state of art in the use of biomarkers for testicular cancer

video-image

Anis Hamid, MD, describes quality of life analysis' impact treatment of metastatic prostate cancer

video-image

Landon Brown, MD, on abiraterone or enzalutamider treatment relating chromosomal instability

video-image

Jeanny Aragon-Ching, MD, on next generation imaging and its impact on prostate cancer treatment

video-image

David Quinn, MD summarizes the EV103 clinical study in urothelial cancer presented at ASCO GU 2020

video-image

Daniel P. Petrylak, MD shares his thoughts on the CARD prostate cancer study presented at ASCO GU 2020

video-image

Rana McKay, MD discusses Checkmate 214 investigating nivolumab + ipilimumab in 1st line RCC patients

video-image

Tom Beer, MD on the data presented at ASCO GU20 investigating atezolizumab and cabozantinib in metastatic castration resistant prostate cancer

video-image

Robert J. Brooks, MD, describes how OneOncology has welcomed his group and impressive resources that help treat cancer patients

video-image

Stephen M. Schleicher, MD, provides examples of how aligning incentives has improved the quality of cancer care delivery while reducing the overall cost of care

video-image

Sibel Blau, MD, shares examples of applied informatics being incorporated into patient management

video-image

Sibel Blau, MD, on the improvement of care via AI, especially in high risk cancer patients

video-image

Kathy Oubre, details how creating tailored patient education has enhanced patient/provider relationships

video-image

Kathy Oubre, considers the predicted surge in cancer patients after the COVID-19 pandemic

video-image

Kathy Oubre, offers best practices and new programs being implemented to safely treat patients during the COVID-19 pandemic

video-image

Steven D'Amato, RPH, BSPharm, on his team's strength as a result of the pandemic and habits to continue

video-image

Kathy Oubre, on cancer patients being given home infusions of treatments during the COVID-19 pandemic

video-image

Jeffrey Patton, MD, elaborates on critical success factors for providing quality cancer care during the COVID-19 pandemic

video-image

Debra Patt, MD, on how informatics work with physicians to aid in treatment decision making at the point of care

video-image

Alti Rahman, MHA, MBA, shares examples of new practices being implemented to safely treat cancer patients through the COVID-19 pandemic